Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured Smartphone-Based COVID-19 Rapid Test

URLhttps://www.biospace.com/article/releases/luminost
SourceBioSpace
Date Published02/16/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Luminostics, Inc.
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Milpitas
State(s) reshored to:CA
If relevant, work nearshored to:-
Industry(ies):Medical Equipment & Supplies
Product(s) reshoredClip COVID Rapid Antigen Test
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy, Lead time/Time to market, Other, Covid-19
Government Incentive dollar amount:$26.1 million
Find Reshoring Articles